Anti-Amyloid beta A4 protein [LY2062430 (Solanezumab, hu266)]

Absolute Antibody

Anti-Amyloid beta A4 protein [LY2062430 (Solanezumab, hu266)]

9

This antibody recognizes amino acids 13-28 of amyloid beta and only recognized soluble form of the amyloid beta peptide. It functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neu

The human IgG1 version of this antibody binds amyloid beta peptide Abeta1-42 with a binding affinity of Kd= 4pM in an in vitro BIAcore assay. The binding characterization of this antibody towards Abeta1-42-BSA conjugate was done using ELISA (US8591894). A study in patients with Alzheimers disease (AD) suggested that a single dose of solanezumab was generally well tolerated, except that mild self-limited symptoms consistent with infusion reactions occurred in few patients when higher doses are given. A dose-dependent change in plasma and CSF Abeta was also observed (PMID: 20375655). The original mouse antibody 266 slowed Abeta accumulation in the brain but failed to deplete Abeta plaques in animal studies (PMID: 11438712). This humanized antibody is likely to have impeded the efflux of soluble Abeta from the brain in patients owing to the formation of Abeta-antibody complexes in the brain interstitial fluid and cerebrospinal fluid, as suggested from animal studies (PMID: 24638135). Phase 1 and 2 studies of solanezumab revealed evidence of target engagement by dose-dependent increases in plasma and CSF total Abeta (PMID: 20375655; 22672770). In the phase 2 study of mild to moderate AD, 12 weeks of solanezumab treatment yielded a dose-dependent increase in CSF-free Abeta42, suggesting a shift in equilibria sufficient to mobilize Abeta42 from plaques (PMID: 22672770). In the first phase III studies, solanezumab did not demonstrate significant benefit for the primary outcomes in either study but showed a favorable safety profile (PMID: 26238576).

ELISA

Research Use Only

Monoclonal

LY2062430 (Solanezumab, hu266)

APP

amyloid beta precursor protein

AAA; ABETA; ABPP; AD1; alpha-sAPP; alzheimer disease amyloid protein; amyloid beta (A4) precursor protein; amyloid beta A4 protein; amyloid precursor protein; amyloid-beta precursor protein; APPI; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); beta-amyloid precursor protein; cerebral vascular amyloid peptide; CTFgamma; CVAP; peptidase nexin-II; PN2; PN-II; preA4; protease nexin-II; testicular tissue protein Li 2

Mouse

IgG2b

Amyloid-beta A4 protein

This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203